AmeriCann /
Our News
ACAN to Present at PIONEERS 2017 in NYC
0
AmeriCann to Present at PIONEERS 2017 Conference by Joseph Gunnar in New York City
Presentation Scheduled for Tuesday, May 2 at 3:30pm EST
DENVER, CO / April 27, 2017 / AmeriCann, Inc. (OTCQX: ACAN), an Ag-Tech company that is developing sustainable, state-of-the-art medical cannabis cultivation properties, announced today that Tim Keogh, Chief Executive Officer, will present at Pioneers 2017 Conference at the Mandarin Oriental Hotel in New York City on Tuesday, May 2, 2017, at 3:30pm EST.
The Pioneers 2017 Conference, presented by Joseph Gunnar, is an exclusive event for institutional and accredited investors who specialize in microcap companies and emerging growth industries to conduct one-on-one meetings with AmeriCann and other participating companies, as well as view formal presentations.
For those interested in attending, please contact Larina Tortotici at ltortorici@jgunnar.com or 212-440-9655 or visit http://www.josephgunnar.
If you are interested in scheduling a 1-on-1 meeting with Tim Keogh of AmeriCann, you may also contact Hayden IR at 917-658-7878 or hart@haydenir.com.
AmeriCann is developing a 53-acre property in Massachusetts (acquired from Boston Beer Company (SAM-NYSE) for $4,475,000 in cash), as the Massachusetts Medical Cannabis Center (the “MMCC”). The MMCC is approved for 1 million square feet and is expected to be one of the largest and most technologically advanced cannabis cultivation facilities in the nation.
The regulated cannabis industry is one of the fastest growing industries in the country. The respected Wall Street firm of Cowen & Co recently released a research report projecting dramatic growth for the industry from the current $7 billion nationally to over $50 billion in ten years.
In November of 2016, Massachusetts, California, Maine, and Nevada voted to legalize recreational marijuana while Arkansas and North Dakota approved medical cannabis initiatives. Florida voters approved medical marijuana in a landslide with over 71% of the vote. With these election results, over 60% of the US Population now live in states where medical cannabis is now legal.
About Joseph Gunnar
Joseph Gunnar & Co., LLC was founded in 1997 as a full service broker-dealer dedicated to assisting investors achieve their financial goals by providing a full array of investment products and vehicles to private and corporate clients. We pride ourselves on our personalized service not often available at many “bulge bracket” firms. We are a member of FINRA & SIPC. For more information, please check out: http://www.josephgunnar.
About AmeriCann
AmeriCann (OTCQX: ACAN) is a publicly traded Ag-Tech company that is developing and sustainable, state-of-the-art medical cannabis cultivation properties. The Company has over 1,000,000 square feet of facilities in the planning and design stages of development. The Company has designed a proprietary line of cannabis infused products which will be branded and licensed to companies in regulated markets.
AmeriCann, Inc. is a Certified B Corp, an acknowledgment of the company’s commitment to social and environmental ethics, transparency, and accountability. AmeriCann became the first public cannabis company to earn this respected accreditation. More information about the Company is available at: www.americann.co, or follow AmeriCann on Twitter at @ACANinfo.
About Massachusetts Medical Cannabis Center
The Massachusetts Medical Cannabis Center is approved for nearly 1,000,000 square feet of medical cannabis cultivation and processing in Freetown, Massachusetts. The state-of-the-art, sustainable, greenhouse project will consist of multiple planned phases for tenants in the Massachusetts medical marijuana market. AmeriCann’s Cannopy System uniquely combines expertise from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation to create superior facilities and procedures.
The first phase of the project consists of 130,000 sq. ft. of cultivation and processing infrastructure. AmeriCann can expand the first phase to approximately 600,000 sq. ft., based on patient demand.
